Arsenic trioxide for the treatment of myelodysplastic syndromes

Bibliography

• WAXMAN S, ANDERSON KC: History of the development of arsenic derivatives in cancer therapy. Oncologist (2001) 6:3–10.
   PubMed Web of Science ®Google Scholar
• CUTLER E, BRADFORD E: Action ofiron, cod-liver oil, and arsenic on the globular richness of the blood?Am. J. Med. Sci. (1878) 75:74–84.
   Google Scholar
• SHEN ZX, CHEN GQ, NI JH et al: Use of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood (1997) 89:3354–3360.
   Google Scholar
• •The first report in the occidental literature of the clinical efficacy of arsenic trioxide.
   Google Scholar
• SOIGNET SL, MASLAK P, WANG ZGet al.: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl. I Med. (1998) 339:1341–1348.
   Google Scholar
• SOIGNET SL, FRANKEL SR, DOUER Det al.: United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia.Clin. °pea (2001) 19:3852–3860.
   Google Scholar
• •The first confirmation that arsenic trioxide can induce cytological and molecular remission in patients with relapsed APL.
   Google Scholar
• COHEN MH, HIRSCHFELD S, FLAMM HONIG S et al.: Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene.Oncologist (2001) 6:4–11.
   Google Scholar
• MILLER WH, JR., SCHIPPER HM, LEE JS, SINGER J, WAXMAN S:Mechanisms of action of arsenic trioxide. Cancer Res. (2002) 62:3893–3903.
   PubMedGoogle Scholar
• •A clear and well documented review article on the mechanisms of action of arsenic trioxide in cancer.
   Google Scholar
• WILLIAMSON PJ, KRUGER AR, REYNOLDS PJ, HAMBLIN TJ, OSCIER DG: Establishing the incidence of myelodysplastic syndrome. Br. Haematol(1994) 87:743–745.
   PubMed Web of Science ®Google Scholar
• BENNETT JM, CATOVSKY D, DANIEL MT et al.: Proposals for the classification of the myelodysplastic syndromes. Br. Haematol (1982) 51:189–199.
   PubMed Web of Science ®Google Scholar
• FENAUX P, MOREL P, ROSE C et al: Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy.Br: J. Haematol (1991) 77:497–501.
   PubMed Web of Science ®Google Scholar
• GREENBERG P, COX C, LEBEAU MMet al.: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood (1997) 89:2079–2088.
   Google Scholar
• ••This study reports on a scoring system forthe prognosis of MDS. It allows to stratify patients according to their prognosis and to compare cohorts of patients between different studies. It represents a landmark in the clinical investigation of MDS and is now widely used.
   Google Scholar
• CHESON BD, BENNETT JM, KANTARJIAN H et al.: Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood (2000) 96:3671–3674.
   PubMed Web of Science ®Google Scholar
• •This article describes standardised response criteria for MDS which are critical for the evaluation and the reporting of the results of investigational therapies in MDS.
   Google Scholar
• HELLSTROM-LINDBERG E, AHLGREN T, BEGUIN Yet al: Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized Phase II study and long-term follow-up of 71 patients. Blood(1998) 92:68–75.
   PubMed Web of Science ®Google Scholar
• NEGRIN RS, HAEUBER DH, NAGLER A et al: Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood (1990) 76:36–43.
   PubMed Web of Science ®Google Scholar
• HELLSTROM-LINDBERG E, GULBRANDSEN N, LINDBERG G et al.: A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life.Br. Haematol (2003) 120:1037–1046.
   PubMed Web of Science ®Google Scholar
• DE WITTE T, ZWAAN F, HERMANS J et al.: Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG) [see comments]. Br. Haematol (1990) 74:151–155.
   PubMed Web of Science ®Google Scholar
• DEEG HJ, SHULMAN HM, ANDERSON JE et al.: Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood (2000) 95:1188–1194.
   PubMedGoogle Scholar
• HELLSTROM-LINDBERG E,ROBERT KH, GAHRTON G et al: A predictive model for the clinical response to low dose ara-C: a study of 102 patients with myelodysplastic syndromes or acute leukaemia. Br. .1. Haematol (1992) 81:503–511.
   PubMed Web of Science ®Google Scholar
• MILLER KB, KIM K, MORRISON FS et al.: The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study. Ann. Hematol (1992) 65:162–168.
   PubMed Web of Science ®Google Scholar
• DE WITTE T, SUCIU S,PEETERMANS M et al.: Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDSof more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). Leukemia (1995) 9:1805–1811.
   Google Scholar
• ESTEY E, THALL P, BERAN M et al.:Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML1) on outcome of AML-type chemotherapy. Blood (1997) 90:2969–2977.
   PubMed Web of Science ®Google Scholar
• •This study shows that MDS patients treated with AML-type regimens have similar outcome than AML patients after adjusting for prognostic covariates. This indicates that the AML/MDS stratification based on blast counts is arbitrary and supports the investigation of intensive regimen in MDS.
   Google Scholar
• BERAN M, SHEN Y, KANTARJIAN H et al.: High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. Cancer (2001) 92:1999–2015.
   PubMed Web of Science ®Google Scholar
• BERAN M, ESTEY E, O'BRIEN S et al: Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J. Clin. Oncol (1999)17:2819–2830.
   PubMed Web of Science ®Google Scholar
• WATTEL E, SOLARY E, LELEU X et al.:A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Francais des Myelodysplasies. Group Ouest-Est d'etude des Leucemies aigues myeloides. Leukemia (1999) 13:524-529 [In Process Citation].
   Google Scholar
• DE WITTE T, VAN BIEZEN A, HERIVIANS J et al.: Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. Blood (1997) 90:3853–3857.
   Google Scholar
• OOSTERVELD M, MUUS P, SUCIU S et al.: Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors. Leukemia (2002) 16:1615–1621.
   PubMed Web of Science ®Google Scholar
• LIST A, BERAN M, DIPERSIO J et al.:Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes. Leukemia (2003) 17:1499–1507.
   PubMed Web of Science ®Google Scholar
• •This article reviews the biology of MDS and its relevance to arsenic trioxide biological activities.
   Google Scholar
• CLARK RE, JACOBS A, LUSH CJ, SMITH SA: Effect of 13-cis-retinoic acid on survival of patients with myelodysplastic syndrome. Lancet (1987) 1:763–765.
   PubMed Web of Science ®Google Scholar
• GOLD EJ, MERTELSMANN RH, ITRI LM et al.: Phase I clinical trial of 13-cis-retinoic acid in myelodysplastic syndromes. Cancer Treat. Rep. (1983) 67:981–986.
   PubMedGoogle Scholar
• PICOZZI VJ, JR., SWANSON GF, MORGAN R, HECHT F,GREENBERG PL: 13-cis retinoic acid treatment for myelodysplastic syndromes. Clin. Oncol (1986) 4:589–595.
   Google Scholar
• KOEFFLER HP, HEITJAN D, MERTELSMANN R et al.: Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disorders. Blood (1988) 71:703–708.
   PubMed Web of Science ®Google Scholar
• AGUAYO A, KANTARJIAN HM, ESTEY EH et al.: Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer (2002) 95:1923–1930.
   PubMed Web of Science ®Google Scholar
• AGUAYO A, KANTARJIAN H, MANSHOURI T et al: Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood (2000) 96:2240–2245.
   PubMed Web of Science ®Google Scholar
• ZORAT F, SHETTY V, DUTT D et al.: The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes.Br. Haematol (2001) 115:881–894.
   PubMed Web of Science ®Google Scholar
• RAZA A, MEYER P, DUTT D et al: Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood (2001) 98:958–965.
   PubMed Web of Science ®Google Scholar
• •The first study demonstrating the clinical efficacy of thalidomide in MDS.
   Google Scholar
• GILES FJ, STOPECK AT,SILVERMAN LR et al: 5U5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia ormyelodysplastic syndromes. Blood (2003) 102:795–801.
   PubMed Web of Science ®Google Scholar
• GILES FJ: New drugs in acute myeloid leukemia. Curr. Oncol Rep. (2002) 4:369–374.
   PubMedGoogle Scholar
• DASKALAKIS M, NGUYEN TT, NGUYEN C et al: Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood(2002) 100:2957–2964.
   PubMed Web of Science ®Google Scholar
• LUBBERT M, WIJERMANS P, KUNZMANN R et al.: Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine. Br. Haematol (2001) 114:349–357.
   PubMed Web of Science ®Google Scholar
• SILVERMAN LR, DEMAKOS EP, PETERSON BL et al: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.Clin. Oncol (2002) 20:2429–2440.
   Google Scholar
• ••Phase III comparative study whichestablishes the efficacy of 5-azacytidine in MDS.
   Google Scholar
• WIJERMANS P, LOBBERT M, VERHOEF G et al: Low-dose 5-Aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter Phase II study in elderly patients.Clin. Oncol (2000) 18:956–962.
   Web of Science ®Google Scholar
• KORNBLITH AB, HERNDON JE 2"d, SILVERMAN LR et al.: Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized Phase III trial: a Cancer and Leukemia Group B study.Clin. Oncol (2002) 20:2441–2452.
   Google Scholar
• CHEN GQ, SHI XG, TANG W et al: Use of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia (APL): I. As203 exerts dose-dependent dual effects on APL cells. Blood (1997) 89:3345–3353.
   Google Scholar
• •This study shows that low-dose arsenic induces differentiation on a APL-dependent manner, whereas higher doses induce APL-independent apoptosis.
   Google Scholar
• LEHMANN S, BENGTZEN S, PAUL A, CHRISTENSSON B, PAUL C: Effects of arsenic trioxide (As203) on leukemic cells from patients with non-M3 acute myelogenous leukemia: studies of cytotoxicity, apoptosis and the patternof resistance. Ear: Haematol(2001) 66:357–364.
   PubMed Web of Science ®Google Scholar
• CHEN YC, LIN-SHIAU SY, LIN JK:Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis. Cell. Physic] (1998) 177:324–333.
   PubMed Web of Science ®Google Scholar
• CAI X, SHEN YL, ZHU Q et al:Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia (2000) 14:262–270.
   PubMed Web of Science ®Google Scholar
• •This study shows that the apoptotic effects of arsenic are mediated by the redox system.
   Google Scholar
• DAVISON K, COTE S, MADER S, MILLER WH: Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines. Leukemia (2003) 17:931–940.
   PubMed Web of Science ®Google Scholar
• YANG CH, KUO ML, CHEN JC, CHEN YC: Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br. I Cancer (1999) 81:796–799.
   PubMed Web of Science ®Google Scholar
• DAI J, WEINBERG RS, WAXMAN S, JING Y: Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system.aBlood (1999) 93:268–277.
   PubMed Web of Science ®Google Scholar
• GRAD JM, BAHLIS NJ, REIS I et al.: Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood (2001) 98:805–813.
   PubMed Web of Science ®Google Scholar
• LING YH, JIANG JD, HOLLAND JF, PEREZ-SOLER R: Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines.Pharmacol (2002) 62:529–538.
   Google Scholar
• PERKINS C, KIM CN, FANG G, BHALLA KN: Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bel-2, or Bc1-x(L). Blood(2000) 95:1014–1022.
   PubMed Web of Science ®Google Scholar
• MATHAS S, LIETZ A, JANZ M et al.: Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis. Blood(2003) 102:1028–1034.
   PubMed Web of Science ®Google Scholar
• LEW Y, BROWN S, GRIFFIN R, SONG C, KIM J: Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer Res.(1999) 59:6033–6037.
   PubMed Web of Science ®Google Scholar
• ROBOZ GJ, DIAS S, LAM G et al: Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood (2000) 96:1525–1530.
   PubMed Web of Science ®Google Scholar
• •Study documents the in vitro antiangiogenic effects of arsenic.
   Google Scholar
• PARK JW, CHOI YJ, JANG MA et al.: Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and bc1-2 phosphorylation in promonocytic U937 cells. Biochem. Biophys. Res. Commun. (2001) 286:726–734.
   PubMed Web of Science ®Google Scholar
• PARK WH, SEOL JG, KIM ES et al.: Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res. (2000) 60:3065–3071.
   PubMed Web of Science ®Google Scholar
• SOIGNET S, AL E: A clinical and pharmacologic study of arsenic trioxide (ATO). Cancer Res. (2000) 41:543 (Abstract).
   Google Scholar
• BARBEY JT, SOIGNET S: Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide foraacute promyelocytic leukemia.Ann. Intern. Med. (2001) 135:842–843.
   PubMed Web of Science ®Google Scholar
• BARBEY JT, PEZZULLO JC,SOIGNET SL: Effect of arsenic trioxide on QT interval in patients with advanced malignancies. Clin. Oncol (2003) 21:3609–3615.
   Google Scholar
• CAMACHO LH, SOIGNET SL, CHANEL S et al.: Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. 1 Gun. Onto] (2000) 18:2620–2625.
   Google Scholar
• VEY N, DREYFUS F, FENAUX P et al.: Trisenox (arsenic trioxide) in patients with myelodysplastic syndromes (MDS): Preliminary results of a Phase 1/2 study. Hematol (2003) 4:218 (Abstract).
   Google Scholar
• ELLISON R, KIRKAHART B, SINGER J: Updated safety experience with Trisenox (arsenic trioxide) injection. Hematol (2003) 4:216.
   Google Scholar
• LIST A, SCHILLER G, MASON J, DOUER D, ELLISON R: Trisenox (arsenic trioxide) in patients with myelodysplastic syndromes (MDS): Preliminary findings in a Phase II clinical study. Hematol(2003) 4:218 (Abstract).
   Google Scholar
• ALBITAR M, MANSHOURI T, SHEN Y et al.: Myelodysplastic syndrome is not merely 'preleukemia'. Blood (2002) 100:791–798.
   PubMed Web of Science ®Google Scholar